Plum SEC
  • Korean Market
  • Privacy Policy

Korean Market

  • Reset (View All)

  • ★★★★★
  • ★★★★
  • ★★★
  • ★★
  • ★

  • ★

  • ★
  • ★★
  • ★★★
  • ★★★★
  • ★★★★★
All Disclosures
EXCH
OSCOTEC
★★★★

OSCOTEC Signs Global License Agreement for SYK Inhibitor Cebidoplenib - $25M Upfront and Up to $640M Milestones, Enhancing Shareholder Value

  06/01/2026, 04:08 PM
OWNR
OSCOTEC
★

Samsung Asset Management reduces OSCOTEC stake from 5.14% to 4.11%... maintains simple investment purpose

  05/29/2026, 04:05 PM
EXCH
OSCOTEC
★

IND Approval for Phase 1 Bioequivalence Study of SKI-O-703 (Formulation Change)

  05/22/2026, 04:51 PM
OWNR
OSCOTEC
★

Tiger Asset Management increases stake in OSCOTEC to 5.09% (simple investment purpose)

  05/22/2026, 02:45 PM
PERI
OSCOTEC
★

OSCOTEC Q1 2026: Consolidated Loss but Parent Turns Profitable, Sanofi Deal Positive

  05/14/2026, 04:36 PM
EXCH
OSCOTEC
★

Holding of IR Meeting

  05/14/2026, 03:54 PM
EXCH
OSCOTEC
★★★

OscoTech to Receive $5.1M Milestone from Yuhan's European Commercialization of EGFR Cancer Drug

  05/14/2026, 03:08 PM
EXCH
OSCOTEC
★

Notice of IR Event Hosted by IBK Investment & Securities

  05/07/2026, 03:27 PM
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.25
The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.